Home / Stocks / Natural Capsules Limited
NATCAPSUQ

Natural Capsules Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹132.83

Change

-6.13 (-4.41%)

Open

₹138.69

Prev. Close

₹138.96

Day High

₹140.45

Day Low

₹132.02

Volume Analysis

Traded

7,368

Delivered

1,724

Delivery %

68.47%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (5)

  • •Trading within 3% of its 52-week low (₹131.0)
  • •Low return on equity (-9.45%)
  • •Promoter holding is falling
  • •Below-average fundamentals quality score (38/100)
  • •Low operating margin (1.6%)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹146.61 ₹143.53 ₹138.18 ₹135.1 ₹129.75 ₹126.67 ₹121.32
Fibonacci ₹143.53 ₹140.31 ₹138.32 ₹135.1 ₹131.88 ₹129.89 ₹126.67
Camarilla ₹135.15 ₹134.38 ₹133.6 ₹135.1 ₹132.06 ₹131.28 ₹130.51

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

-26.62%

1 Week

-12.98%

1 Month

-14.91%

3 Months

-12.54%

6 Months

-12.21%

1 Year

-28.43%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹62.47

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

-11.17%

Net margin -11.22% × asset turnover 0.76x × equity multiplier 1.31x

Company Overview

Sector

Healthcare

Market Cap

₹144 Cr

ROE

-9.45%

Book Value

₹209.0

Face Value

₹10.0

Source: Screener.in (Consolidated figures) — data as of 19 Nov 2026. Not investment advice.

TopFund Analysis

Natural Capsules Limited scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 38/100. The strongest factor is Financial Strength (86/100), while Momentum (7/100) is the weakest area to weigh before deciding. Notably: Trading within 3% of its 52-week low (₹131.0); low return on equity (-9.45%).

TopFund Score — Fundamentals Quality

38/100 — Weak

Data confidence: 76/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

86

Growth

54

Valuation

22

Cash Flow

29

Corporate Governance

43

Momentum

7

Institutional Ownership

20

Business Quality

21

Risk & Volatility

42

Liquidity

48

From Screener.in

  • +Company has reduced debt.
  • +Stock is trading at 0.66 times its book value
  • −Company has low interest coverage ratio.
  • −Company has a low return on equity of -2.06% over last 3 years.
  • −Contingent liabilities of Rs.75.2 Cr.
  • −Earnings include an other income of Rs.1.57 Cr.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Natural Capsules reports Q2 FY27 revenue of ₹51.15 crore and H1 revenue of ₹99.86 crore.

Copy of Investor Presentation in connection with Q2 Financial Results.

Unaudited Financial Results for Quarter and Half Yearly ended September 20, 2026, has been published in Business Line (English Newspaper) and Sanjevani (Kannada Newspaper).

Conference call on 19 November 2026 to discuss Q2 and H1 FY27 results and business outlook.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 38 40 40 39 41 44 45 45 46 38 58 49 51
Expenses + 32 35 36 35 37 40 41 45 47 40 57 48 48
Operating Profit 5 5 4 4 5 4 4 0 -1 -2 1 1 3
OPM % 13.65% 11.81% 10.22% 11.15% 10.92% 9.74% 9.76% 0.71% -1.94% -6.15% 2.28% 2.3% 5.88%
Other Income + 0 1 1 0 0 0 0 0 0 0 1 0 0
Interest 1 1 1 1 2 2 2 3 3 3 3 3 3
Depreciation 2 2 2 2 2 2 2 4 4 4 4 4 5
Profit before tax 2 2 1 1 1 1 1 -6 -8 -9 -5 -6 -5
Tax % 27.1% 32.96% 32.17% 21.79% 201.64% 78.43% 41.57% -8.09% -9.09% -21.7% -1.97% -1.54% -7.86%
Net Profit + 2 1 1 1 -1 0 1 -6 -7 -7 -5 -6 -4
EPS in Rs 2 1 1 1 -1 0 0 -5 -4 -5 -3 -3 -1
Raw PDF — — — — — — — — — — — — —
YoY Sales growth -17 -12 7 4 10 10 12 15 11 -14 30 8 12

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 67 62 54 55 60 62 80 135 170 155 169 187 196
Expenses + 56 52 49 49 55 56 68 110 135 135 151 188 193
Operating Profit 12 10 5 6 5 5 11 26 35 20 18 -1 3
OPM % 17.0% 16.0% 10.0% 10.0% 8.0% 9.0% 14.0% 19.0% 21.0% 13.0% 10.0% -0.5% 1.6%
Other Income + 1 1 0 1 1 1 3 1 1 2 1 2 2
Interest 1 1 1 0 1 1 1 2 4 5 7 12 11
Depreciation 4 4 4 4 3 4 4 5 7 9 9 17 18
Profit before tax 8 6 0 2 2 1 9 19 25 8 3 -28 -25
Tax % 25.0% 28.0% -103.0% 34.0% 7.0% 38.0% 24.0% 28.0% 26.0% 31.0% 78.0% -12.0% —
Net Profit + 6 4 1 1 2 1 7 14 18 6 1 -25 -22
EPS in Rs 9 6 1 1 3 1 9 18 20 6 0 -16 -12
Dividend Payout % 14.0% 20.0% 99.0% 56.0% 32.0% 43.0% 9.0% 5.0% 5.0% 0.0% 0.0% 0.0% —
Sales growth 15 -8 -14 — 9 3 29 70 26 -9 9 11 9

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 42 50 48 48 49 49 56 76 114 194 176 165 207
Borrowings + 5 6 3 0 5 6 10 53 97 109 152 162 117
Other Liabilities + 11 16 14 19 14 14 27 29 70 64 81 87 88
Total Liabilities 63 77 71 73 75 76 99 165 290 377 419 424 423
Fixed Assets + 29 30 26 22 24 24 38 66 97 103 284 274 269
CWIP 2 0 0 1 2 2 7 20 88 144 0 4 4
Investments 0 5 5 5 5 6 0 0 0 3 3 3 3
Other Assets + 32 42 40 45 43 45 54 79 105 127 133 143 147
Total Assets 63 77 71 73 75 76 99 165 290 377 419 424 423
Equity Capital 5 6 6 6 6 6 6 7 9 9 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 5 3 2 5 2 7 13 -1 17 -8 27 11
Cash from Investing Activity + -4 -8 0 -1 -7 -6 -16 -46 -105 -73 -44 -11
Cash from Financing Activity + -1 4 -2 -4 4 -1 3 48 87 82 16 -1
Net Cash Flow 0 0 0 0 -1 0 0 1 0 1 -2 0
Free Cash Flow 2 1 2 4 -5 2 -11 -47 -88 -79 -18 -1
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 60 51 41 97 57 144 134 17 64 -32 162 -1,634

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 56.57% → 50.92%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 42.13% 42.13% 43.25% 48.39% 48.86% 48.8% 48.75% 48.73% 48.74% 48.96% 49.09% 48.99%
Promoters 56.57% 56.57% 56.57% 51.59% 51.13% 51.21% 51.26% 51.26% 51.26% 51.04% 50.92% 50.92%
FII 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.08%
DII 1.31% 1.31% 0.18% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0% 0.0%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Natural Capsules Limited (this stock) 144 — 0.66 -9.45%
Bal Pharma Ltd. 135 17.1 1.58 7.79%
Parnax Lab Ltd. 125 14.6 1.27 14.2%
Makers Laboratories Ltd. 169 22.6 2.15 3.17%
Balaxi Pharma Ltd 175 51.8 0.69 0.59%
Alpa Laboratories Ltd 109 52.0 0.59 8.38%
Take Limited 192 22.0 5.6 16.5%

Which Mutual Funds Hold Natural Capsules Limited?

Frequently Asked Questions about Natural Capsules Limited

Community Sentiment

What are other investors saying about Natural Capsules Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.